Want to see LGVN full AI Analyst Report?
LGVN Stock Chart & Stats
$1.10
-$0.07(-3.68%)
At close: 4:00 PM EST
$1.10
-$0.07(-3.68%)
Day’s Range― - ―
52-Week Range$0.48 - $1.80
Previous CloseN/A
Volume215.49K
Average Volume (3M)473.11K
Market Cap
$19.65M
Enterprise Value$10.77
Total Cash (Recent Filing)$15.76M
Total Debt (Recent Filing)$748.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding30,148,947
10 Day Avg. Volume706,553
30 Day Avg. Volume473,105
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.50Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$1.49M
Bulls Say, Bears Say
Bulls Say
Strong IP & Regulatory DesignationsA broad global patent portfolio and multiple FDA expedited designations provide durable barriers to entry, strengthen negotiating leverage for partnerships or licensing, and can accelerate regulatory interactions across indications — improving long‑term commercialization optionality.
Completed ELPIS II Enrollment & Near‑term CatalystFull enrollment materially reduces execution risk tied to patient recruitment and creates a clear, near‑term clinical milestone. A timely topline readout enables definitive data-driven partnership, regulatory engagement, or program reprioritization decisions that alter the company’s strategic path.
Low Financial LeverageMinimal debt exposure preserves financial flexibility, limits interest obligations, and reduces short‑term solvency risk. For a development‑stage biotech, low leverage makes equity or partnership financings more feasible and less constrained by fixed repayment burdens.
Bears Say
Limited Cash RunwayWith cash funding projected only into Q4 2026, the company faces a near‑term financing requirement. Persistent trial costs mean financing timing and terms will materially affect dilution, program pacing, and the ability to complete planned regulatory interactions without partnership concessions.
Regulatory Uncertainty On Primary EndpointThe FDA’s rejection of RVEF and loss of 'pivotal' designation raises the evidentiary bar and complicates the approval pathway. This structural regulatory uncertainty can force additional analyses or new trials, lengthening timelines and increasing capital needs regardless of current enrollment.
Sustained Cash Burn & Minimal RevenueVery small revenues versus substantial recurring losses and negative operating cash flow indicate the business is not self‑funding. Over the medium term, continued cash burn necessitates external capital or partnerships and makes long‑term sustainability contingent on clinical success or deal execution.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.47 and its highest was $1.80 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $19.65M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Aug 07, 2026 which is in 18 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.012.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -0.18.
How many shares outstanding does Longeveron have?
Longeveron has 30,148,947 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -7.02%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Longeveron
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
LGVN Stock 12 Month Forecast
Average Price Target
$5.50
▲(400.00% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
13.87% Insiders
2.19% Mutual Funds
0.04% Other Institutional Investors
81.97% Public Companies and
Individual Investors